Latest news with #CSCC
Korea Herald
29-07-2025
- Business
- Korea Herald
Cadence to plead guilty, pay $140m to US for China sales
Cadence Design agreed to plead guilty and pay more than $140 million to resolve US charges for selling its chip design products to a Chinese military university believed to be involved in simulating nuclear explosions, the Justice Department said Monday. Cadence is accused of violating export controls by illegally selling chip design software and hardware to front companies representing China's National University of Defense Technology. NUDT's supercomputers are thought to support nuclear explosive simulation and military simulation activities, according to US Commerce Department notices restricting shipments to the university. San Jose, California-based Cadence noted a charge related to the legal proceedings in its quarterly results, also released Monday. In a filing with the US Securities and Exchange Commission, the company said it was "pleased" to reach settlements with the Justice and Commerce departments. The deal shows the US is still willing to enforce US export controls on China, even as it relaxes some of the restrictions as part of negotiations. NUDT was put on the Commerce Department's restricted trade list in 2015 to keep it from using US technology to power its supercomputers, according to department postings. Other aliases and locations were added to the university's listing in 2019 and 2022, including Hunan Guofang Keji University, Central South CAD Center and CSCC. Cadence and its subsidiary Cadence China exported electronic design automation tools at least 56 times to CSCC between 2015 and 2020, with certain Cadence China employees facilitating business with NUDT while knowing CSCC was an alias for the restricted university, court papers said. They also transferred EDA tools to Phytium Technology Co, a semiconductor company closely associated with NUDT, until 2021, without obtaining required licenses, according to court papers. Cadence agreed to plead guilty to one count of conspiracy to commit export control violations. It is expected to be on probation for three years, meaning it cannot commit any further violations and has to fulfill its obligations under the plea agreement. The $140 million covers criminal penalties, forfeiture and a civil penalty imposed by the Commerce department. Cadence, whose customers include major semiconductor manufacturers and companies such as Nvidia and Qualcomm, is known for its electronic computer-aided design software. Cadence was run for over a decade by Lip-Bu Tan, a Malaysian-born Chinese American business executive appointed chief executive of Intel in March. Tan was CEO of Cadence from 2008 through December 2021, which includes the period the sales took place, and was executive chairman until May 2023. The US investigation into Cadence, which began more than four years ago, involved 'historical sales by Cadence to customers in China,' according to a company filing. Cadence received a subpoena from the US Commerce Department in February 2021, demanding records related to certain customers in China. A related November 2023 subpoena followed from the Justice Department over the company's business activity in China. Entities are placed on the restricted trade list, formerly known as the Entity List, for activities deemed contrary to US national security or foreign policy interests. US companies are not allowed to ship goods and technology to them without licenses from the Commerce Department, which are generally denied. Electronic design automation tools are key to designing chips and verifying that they are bug-free. NUDT has developed chips to power university supercomputers, including Tianhe-2, once touted as the world's best supercomputer, which the US believes has been used in research on or the development of nuclear explosive devices. Twelve percent of Cadence's revenue came from China last year, down from 17 percent in 2023, amid regulatory developments and geopolitical tensions. (Reuters)
Jordan News
22-06-2025
- Business
- Jordan News
Civil Service Consumer Corporation Announces Discounts on Over 250 Items - Jordan News
Amman – The Civil Service Consumer Corporation (CSCC) announced promotional discounts on more than 250 food and non-food items, starting Monday and running through Thursday evening, July 3. The discounts range from 7% to 30%. اضافة اعلان Acting Director General Eng. Essam Al-Jarrah stated in a press release on Sunday that the offers mainly include essential goods such as rice, sugar, vegetable oils, tea, powdered milk, legumes, and tahini. These discounts will be available across all 69 CSCC branches throughout the Kingdom's governorates and districts, with sufficient quantities to meet consumer demand. He encouraged consumers to visit the corporation's official Facebook page to view full details of the discounted items and their prices. Al-Jarrah added that consumers in the capital, Amman, can also place orders via the online store at or through the CSCC mobile app available on Android and iOS under the name 'Civil Service Consumer Store.' He emphasized that these discounts are part of the corporation's ongoing efforts to ease the financial burden on citizens, especially those with low and middle incomes, and to protect them from rising prices. The corporation bases its purchases and sales on strict quality standards and laboratory testing, he said, confirming that all discounted items have passed the required health and safety tests before being made available in stores. Al-Jarrah also noted that citizens can submit suggestions and feedback through official communication channels, including the hotline 4885843, the corporation's Facebook page, direct contact with market managers or customer service, suggestion and complaint boxes at store entrances, and the official website
Yahoo
11-06-2025
- Health
- Yahoo
Biosenta's Tri-Filler(TM) Nanoparticles Achieve 100% Killing of Pathogens at Industry-Low Dose in Peer-Reviewed Studies
Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - June 11, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that two independent, peer-reviewed studies conducted at the University of Calgary confirmed that its proprietary Tri-Filler™ core-shell calcium hydroxide-calcium carbonate (CSCC™) nanoparticles achieved complete (100 %) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides. "Transforming a readily available mineral into a durable, broad-spectrum antimicrobial opens new opportunities for safer surfaces in hospitals, transit systems and homes," said Dr. Mehdi Mohammadi Ashani, lead author of both papers. Key laboratory findings The research, conducted and independently validated by University of Calgary scientists, is detailed in two recent peer-reviewed publications in Colloids and Surfaces A and The Canadian Journal of Chemical Engineering.¹ ² These studies confirmed Tri-Filler's™ potent efficacy against multiple World Health Organization priority bacterial pathogens, including: Gram-negative bacteria: Escherichia coli (E. coli), Pseudomonas aeruginosa Gram-positive bacteria: Staphylococcus aureus (including MRSA) These findings were validated using both Minimum Inhibitory Concentration (MIC) and Minimum Biocidal Concentration (MBC) protocols, with consistent 100% elimination rates at the 2.5 mg/mL threshold across these bacterial strains. Traditional biocides rely on frequent re-application and can trigger resistance or toxicity. The 100 % kill rates reported above were obtained under controlled laboratory conditions. In addition, Biosenta has obtained similar promising results against other significant microbes, including the Gram-positive bacterium Enterococcus faecalis and fungi Candida auris and Candida albicans. These results are currently under preparation for peer-reviewed publication. "Achieving 100 per cent eradication across three WHO-priority species by a more environmentally friendly biocide at such relatively low dose moves Tri-Filler™ into a class of its own and is a decisive step toward safer, longer-lasting antimicrobial surfaces," added Dr. Maen Husein, professor of chemical and petroleum engineering and senior author of the papers. From personal loss to public good Biosenta's president and CEO Am Gill lost his uncle to a hospital-acquired infection. That tragedy drives the company's mission and underpins a $140-thousand donation to the Alberta Centre for Advanced Diagnostics to accelerate nanoparticle research. "We're turning grief into action," Gill said. "Embedding Tri-Filler™ into concrete, paint and coatings will let us stop pathogens at the surface and save lives."What happens next Regulatory filings - Health Canada and U.S. EPA submissions for Tri-Filler™-enabled products are in preparation. Manufacturing scale-up - Bench output already tops 170 kg day; full commercial plant design is under way. About Biosenta Inc. Biosenta Inc. develops innovative antimicrobial products that offer environmentally friendly solutions to a global market. Based in Toronto, Ontario and Calgary, Alberta, the company is dedicated to the advancement of technology that combats microbial growth in various materials. Biosenta's flagship product, Tri-Filler®, represents a breakthrough in antimicrobial technology, providing durable protection against a wide spectrum of bacteria, molds, and fungi. For further inquiries, please contact: Am Gill, President and CEO, Biosenta info@ 416-410-2019 For more information, visit our website: References N. Darwish, M. M. Ashani, A. Mehairi, I. A. Lewis, M. M. Husein, "Synthesis of uniform core-shell calcium hydroxide-calcium carbonate biocidal particles via encapsulation into dry ice," Canadian Journal of Chemical Engineering, 2025, 1. DOI: 10.1002/cjce.25670. N. Darwish, M. M. Ashani, I. A. Lewis, M. M. Husein, "Controlled carbonation of Ca(OH)₂ surface and its application as an antibacterial particle," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2024, 682. DOI: 10.1016/ Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable securities laws ("forward-looking statements"), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company's business, financial condition or results of operations. In that case, the trading price of the Company's common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Disclaimer The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
The Age
07-06-2025
- Health
- The Age
Out of the ashes, a new treatment for a hidden cancer
Keratinocytes, like all healthy cells, carefully follow the instructions coded into your DNA. But when DNA is damaged, most-often through the photons in sunlight smashing into it, the instructions can be garbled. These new instructions can cause the cell to start dividing uncontrollably, eventually forming a cancerous tumour. Loading CSCCs typically appear on the most sun-exposed parts of our skin – the hands, the neck, the scalp or ears – as a firm bump or scaly sore. Bailey recalls 'a scabby sort of thing on my head'. As soon as his doctor saw it, he cut it out. Surgical excision, and sometimes additional radiation therapy, is the typical treatment for CSCC. In more than 90 per cent of cases, simple treatment is entirely curative. 'You cut them out, you send it off, you stitch it up, and they are cured,' says McCormack. But occasionally, the cancer has spread before it is spotted. Of every 100 cases, one to three people will die, as the cancer grows back in their lungs or livers or bones. Deaths from non-melanoma skin cancers have almost doubled in Australia in the past 20 years; globally, CSCC causes more deaths than melanoma does, despite its lack of name-recognition. About 70 per cent of us will get a non-melanoma skin cancer in our lives – hence the high number of deaths, even though the disease itself has a relatively low mortality rate. 'It's so common, people tend to trivialise it a bit,' says the University of the Sunshine Coast's Associate Professor Andrew Dettrick, who has published papers on CSCC. 'Five per cent does not sound like a lot, but it is when you times it by 200,000 people.' A new standard of treatment for an invisible disease If a doctor cuts out the tumour, and then uses beams of radiation to kill any cells they cannot reach, why does cancer sometimes come back? 'They have got microscopic disease left, either in the area that's been treated, or it has already spread. And we don't have any way of knowing that,' says Professor Danny Rischin, head of research for head and neck cancer at the Peter MacCallum Cancer Centre. The focus of Rischin's career has been on stopping that cancer coming back. In 2018, he co-authored a study testing whether Carboplatin, a chemotherapy drug, could prevent relapse. Loading Like many experiments, it did not work. The drug did not improve survival. But scientists often learn more from failure than success. Rischin's team were able to isolate a subgroup of CSCC patients within the trial who had certain features that put them at a dramatically higher rate of cancer recurrence. 'They were in need of better treatment,' he says. For this group, Rischin's team turned to one of the medicines that has revolutionised cancer treatment in the past decade: checkpoint inhibitors. Our immune system needs to run certain checks to ensure it is attacking an enemy, not one of our own cells. Cancer often takes advantage of this, generating its own codes to pass the checks. Using genetically modified antibodies, scientists in the past two decades have learned to block our own immune system's checkpoints. 'It unmasks the cancer cell, so your immune system can see it again,' says Dettrick. Perhaps a souped-up immune system could ferret out the microscopic cancers the surgeons could not? In a study sponsored by the therapy's manufacturer, published in the New England Journal of Medicine, Rischin's team randomised 415 patients, who had been treated for CSCC but had a risk of recurrence, between immunotherapy and a placebo: 87 per cent of patients on the therapy were still disease-free after 24 months, compared to 64 per cent on the placebo. About 10 per cent of patients getting the therapy had severe side effects, and one died – consistent with the normal side effects from immunotherapy.
Sydney Morning Herald
07-06-2025
- Health
- Sydney Morning Herald
Out of the ashes, a new treatment for a hidden cancer
Keratinocytes, like all healthy cells, carefully follow the instructions coded into your DNA. But when DNA is damaged, most-often through the photons in sunlight smashing into it, the instructions can be garbled. These new instructions can cause the cell to start dividing uncontrollably, eventually forming a cancerous tumour. Loading CSCCs typically appear on the most sun-exposed parts of our skin – the hands, the neck, the scalp or ears – as a firm bump or scaly sore. Bailey recalls 'a scabby sort of thing on my head'. As soon as his doctor saw it, he cut it out. Surgical excision, and sometimes additional radiation therapy, is the typical treatment for CSCC. In more than 90 per cent of cases, simple treatment is entirely curative. 'You cut them out, you send it off, you stitch it up, and they are cured,' says McCormack. But occasionally, the cancer has spread before it is spotted. Of every 100 cases, one to three people will die, as the cancer grows back in their lungs or livers or bones. Deaths from non-melanoma skin cancers have almost doubled in Australia in the past 20 years; globally, CSCC causes more deaths than melanoma does, despite its lack of name-recognition. About 70 per cent of us will get a non-melanoma skin cancer in our lives – hence the high number of deaths, even though the disease itself has a relatively low mortality rate. 'It's so common, people tend to trivialise it a bit,' says the University of the Sunshine Coast's Associate Professor Andrew Dettrick, who has published papers on CSCC. 'Five per cent does not sound like a lot, but it is when you times it by 200,000 people.' A new standard of treatment for an invisible disease If a doctor cuts out the tumour, and then uses beams of radiation to kill any cells they cannot reach, why does cancer sometimes come back? 'They have got microscopic disease left, either in the area that's been treated, or it has already spread. And we don't have any way of knowing that,' says Professor Danny Rischin, head of research for head and neck cancer at the Peter MacCallum Cancer Centre. The focus of Rischin's career has been on stopping that cancer coming back. In 2018, he co-authored a study testing whether Carboplatin, a chemotherapy drug, could prevent relapse. Loading Like many experiments, it did not work. The drug did not improve survival. But scientists often learn more from failure than success. Rischin's team were able to isolate a subgroup of CSCC patients within the trial who had certain features that put them at a dramatically higher rate of cancer recurrence. 'They were in need of better treatment,' he says. For this group, Rischin's team turned to one of the medicines that has revolutionised cancer treatment in the past decade: checkpoint inhibitors. Our immune system needs to run certain checks to ensure it is attacking an enemy, not one of our own cells. Cancer often takes advantage of this, generating its own codes to pass the checks. Using genetically modified antibodies, scientists in the past two decades have learned to block our own immune system's checkpoints. 'It unmasks the cancer cell, so your immune system can see it again,' says Dettrick. Perhaps a souped-up immune system could ferret out the microscopic cancers the surgeons could not? In a study sponsored by the therapy's manufacturer, published in the New England Journal of Medicine, Rischin's team randomised 415 patients, who had been treated for CSCC but had a risk of recurrence, between immunotherapy and a placebo: 87 per cent of patients on the therapy were still disease-free after 24 months, compared to 64 per cent on the placebo. About 10 per cent of patients getting the therapy had severe side effects, and one died – consistent with the normal side effects from immunotherapy.
